RE-LY Trial — Dabigatran vs Warfarin in Atrial Fibrillation
Landmark trial establishing leech-inspired oral anticoagulant dabigatran for stroke prevention
Resumen
The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial compared dabigatran — a direct thrombin inhibitor inspired by leech hirudin — against warfarin for stroke prevention in atrial fibrillation. The trial (n=18,113) demonstrated non-inferiority and, at higher doses, superiority over warfarin with lower intracranial hemorrhage rates.
Por qué esto importa para la hirudoterapia
Dabigatran represents the most transformative drug to emerge from leech biology. This NEJM landmark trial led to FDA approval and fundamentally changed anticoagulation practice. It is the definitive example of bench-to-bedside translation from leech salivary pharmacology.
Citación
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Connolly SJ et al. · New England Journal of Medicine, 2009
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: March 18, 2026